Reuters logo
BRIEF-Portola Pharmaceuticals says entered into commercial supply agreement with CMC Icos Biologics
2016年12月15日 / 晚上11点22分 / 9 个月前

BRIEF-Portola Pharmaceuticals says entered into commercial supply agreement with CMC Icos Biologics

Dec 15 (Reuters) - Portola Pharmaceuticals Inc :

* Portola Pharmaceuticals Inc- pursuant to agreement, company will purchase from CMC commercial supply of andexanet alfa- sec filing

* Portola Pharmaceuticals- pursuant to agreement, cmc will provide other services supporting co’s regulatory applications in United States, European Union

* Portola Pharmaceuticals Inc- under agreement, co is required to purchase a fixed number of batches of andexanet alfa from cmc from 2017 through 2018

* Portola Pharmaceuticals Inc- on December 9, co entered into an amended and restated commercial supply agreement with CMC Icos Biologics Inc

* Portola Pharmaceuticals Inc- company or CMC may also terminate agreement prior to February 15, 2017 Source text - bit.ly/2gGKEgd Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below